Neue Therapiemodalitäten bei Mukoviszidose

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Der Pneumologe

• Publication date

  2019-01-09

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s10405-018-0220-8
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• VX-659–Tezacaftor–Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles

  2020cited by this paper
• P080 The European Cystic Fibrosis Society Patient Registry (ECFSPR) data validation programme: accuracy and consistency of data

  2019cited by this paper
• Translational research to enable personalized treatment of cystic fibrosis.

  2018cited by this paper
• Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study.

  2018cited by this paper
• VX‐659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

  2018cited by this paper
• VX‐445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

  2018cited by this paper
• Altering Metabolic Profiles of Drugs by Precision Deuteration 2: Discovery of a Deuterated Analog of Ivacaftor with Differentiated Pharmacokinetics for Clinical Development

  2017cited by this paper
• Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

  2017cited by this paper
• Cystic Fibrosis Diagnosis and Treatment

  2017cited by this paper
• Correcting CFTR folding defects by small‐molecule correctors to cure cystic fibrosis

  2017cited by this paper
• Bypassing CFTR dysfunction in cystic fibrosis with alternative pathways for anion transport

  2017cited by this paper
• Pharmacokinetics and safety of cavosonstat (N91115) in healthy and cystic fibrosis adults homozygous for F508DEL-CFTR.

  2017cited by this paper
• Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.

  2017cited by this paper
• Tezacaftor–Ivacaftor in Residual‐Function Heterozygotes with Cystic Fibrosis

  2017cited by this paper
• Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis

  2016cited by this paper
• ECFS Patient Registry : annual data Report : 2013 data

  2016cited by this paper
• Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR

  2016cited by this paper
• Progress in therapies for cystic fibrosis.

  2016cited by this paper
• Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial

  2015cited by this paper
• Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.

  2015cited by this paper
• Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.

  2014cited by this paper
• Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.

  2014cited by this paper
• The role of the bacterial microbiome in lung disease

  2013cited by this paper
• Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene

  2013cited by this paper
• Tgf-β1 Inhibits Cftr Biogenesis and Prevents Functional Rescue of ΔF508-Cftr in Primary Differentiated Human Bronchial Epithelial Cells

  2013cited by this paper
• Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients.

  2013cited by this paper
• Novel opportunities for CFTR-targeting drug development using organoids

  2013cited by this paper
• Nongenetic influences on cystic fibrosis outcomes

  2011influential reference
• A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

  2011cited by this paper
• Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2

  2011cited by this paper
• Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.

  2010cited by this paper
• Cystic fibrosis: genotypic and phenotypic variations.

  1995cited by this paper

• No citing papers are available for this paper.